Patents Examined by Taina D Matos Negron
  • Omega-3 pentaenoic acid compositions and methods of use
    Patent number: 10058521
    Abstract: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: August 28, 2018
    Assignee: MATINAS BIOPHARMA INC.
    Inventors: George Bobotas, Abdel Aziz Fawzy
  • Treatment of mastocytosis with masitinib
    Patent number: 10045978
    Abstract: The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 14, 2018
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Adamantane or pinene derivatives for use in the treatment of chlamydiales infections
    Patent number: 10039727
    Abstract: The present invention relates to a method for treating a Chlamydiales infection comprising the administration of a therapeutically effective amount of a compound of formula (I) to a subject in need thereof: W-L1-NH-L2-Ar?? (I) Wherein W, L1, L2 and Ar are as defined in claim 1.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: August 7, 2018
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Daniel Gillet, Julien Barbier, Jean-Christophe Cintrat, Valérie Pons, Thomas Rudel, Jo-Ana Herweg, Annette Fischer
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10034845
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 31, 2018
    Assignee: lo Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Procaspase-activating compounds and methods
    Patent number: 10022371
    Abstract: The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: July 17, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Paul J. Hergenrother
  • Fungicidal composition and method for controlling plant diseases
    Patent number: 10015964
    Abstract: The present invention provides a fungicidal composition useful as an agricultural and horticultural fungicide having remarkably improved controlling effects against plant diseases, and a method for controlling plant diseases using the composition. A fungicidal composition comprising, as active ingredients, (a) 3-(2,3,4-trimethoxy-6-methylbenzoyl)-5-chloro-2-methoxy-4-methylpyridine (pyriofenone) or its salt and (b) at least one fungicide selected from the group consisting of bixafen, fluxapyroxad, penflufen, isopyrazam, fluopyram, ametoctradin, fenpyrazamine and sedaxane, and a method for controlling plant diseases, which comprises applying the fungicidal composition to plants.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: July 10, 2018
    Assignee: Ishihara Sangyo Kaisha, Ltd.
    Inventors: Munekazu Ogawa, Yuzuka Kawai
  • Metalloinsertor conjugates
    Patent number: 9969858
    Abstract: A composition including a metalloinsertor conjugate that specifically targets mismatch repair (MMR)-deficient cells includes a complex represented by Formula I. Mm+(L1)(L2)(L3)(L4)(L5)??Formula I Selective cytotoxicity may be induced in MMR-deficient cells upon uptake of the metalloinsertor conjugate. Metalloinsertor complexes conjugated with platinum (Pt) may allow for more specific targeting of platinum anticancer agents.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: May 15, 2018
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Alyson Weidmann, Jacqueline K. Barton
  • TRPA1 modulators
    Patent number: 9951046
    Abstract: This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: April 24, 2018
    Assignee: Algomedix, Inc.
    Inventors: Jeffrey M. Herz, Edward A Kesicki
  • Carbapenem antibacterials with gram-negative activity
    Patent number: 9937151
    Abstract: The present invention provides ?-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 10, 2018
    Assignee: FOB Synthesis, Inc.
    Inventors: Woo-Baeg Choi, Ewa Gruszecka-Kowalik, Hyung-Yeul Joo, Shuangpei Liu, Shuli Mao, Yongfeng Li, Deog-Il Kim
  • Quinoline-based kinase inhibitors
    Patent number: 9932320
    Abstract: The present disclosure is generally directed to compounds of formula (I) which can inhibit AAKI (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAKI.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: April 3, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, John E. Macor, Joanne J. Bronson, Bireshwar Dasgupta, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof
    Patent number: 9926308
    Abstract: Compounds of formula I wherein R1, LP, n, HetAr1, and HetAr2 are as defined herein, and salts thereof, pharmaceutical compositions containing these compounds, and methods for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, such as diabetes, dislipidemia, or obesity, by administering to a patient in need thereof these compounds or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bernd Nosse, Matthias Eckhardt, Frank Himmelsbach, Elke Langkopf, Neil J. Ashweek, Nicole Harriott
  • 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
    Patent number: 9926304
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 27, 2018
    Assignee: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • Methods of treating cancer using compositions comprising perillyl alcohol derivative
    Patent number: 9913838
    Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: March 13, 2018
    Assignee: NeOnc Technologies, Inc.
    Inventor: Thomas Chen
  • Inhibitors of influenza viruses replication
    Patent number: 9908878
    Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: March 6, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Randy S. Bethiel, Michael J. Boyd, Ioana Davies, Hongbo Deng, John P. Duffy, Luc J. Farmer, Huai Gao, Wenxin Gu, Joseph M. Kennedy, Brian Ledford, Mark W. Ledeboer, Francois Maltais, Emanuele Perola, Tiansheng Wang
  • TGF-beta inhibitors
    Patent number: 9884868
    Abstract: Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R? are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: February 6, 2018
    Assignees: Rigel Pharmaceuticals, Inc., Bristol-Myers Squibb Company
    Inventors: Todd Kinsella, Marina Gelman, Hui Hong, Ihab S. Darwish, Rajinder Singh, Jiaxin Yu, Robert M. Borzilleri, Upender Velaparthi, Peiying Liu, Chetan Darne, Hasibur Rahaman, Jayakumar Sankara Warrier
  • Composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient
    Patent number: 9884041
    Abstract: Provided is a composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient. The composition of the present invention can be used to advantage as a drug or functional food composition which not only exhibits activity in the prevention or treatment of obesity, hyperlipidaemia or fatty liver but which also causes a significant reduction in fasted blood sugar and blood insulin concentration and hence has an effect in improving Type-2 diabetes or insulin resistance and also improves metabolic disorder which is closely associated therewith.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: February 6, 2018
    Assignee: YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC.
    Inventor: Tae Sun Park
  • Proliposomal testosterone formulations
    Patent number: 9844557
    Abstract: Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: December 19, 2017
    Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLC
    Inventors: Guru V. Betageri, Ramachandran Thirucote, Veeran Gowda Kadajji
  • Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster
    Patent number: 9814743
    Abstract: The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: November 14, 2017
    Assignee: DEVIREX AG
    Inventors: Peter Vitins, Marcel Langenauer, Paul Martin Scherer
  • Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
    Patent number: 9809578
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 7, 2017
    Assignee: Array BioPharma Inc.
    Inventors: Barbara J. Brandhuber, Yutong Jiang, Gabrielle R. Kolakowski, Shannon L. Winski
  • Methods of colchicine administration
    Patent number: 9789108
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: October 17, 2017
    Assignee: Hikma Pharmaceuticals LLC
    Inventor: Murray Ducharme